Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis
Lotte S. Spekhorst, Daphne S. Bakker, Julia Drylewicz, et al.
Allergy (2022) Vol. 77, Iss. 11, pp. 3398-3407
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Two‐year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months
Rik Johannes Leonardus van der Lans, Josje Janna Otten, Gwijde Flavius Jacobus Petrus Maria Adriaensen, et al.
Allergy (2023) Vol. 78, Iss. 10, pp. 2684-2697
Open Access | Times Cited: 39
Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry
Lotte S. Spekhorst, Celeste M. Boesjes, Laura Loman, et al.
British Journal of Dermatology (2023) Vol. 189, Iss. 3, pp. 327-335
Open Access | Times Cited: 23
Real‐world data show sustained therapeutic effects of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) over 3 years
Patrick Huber, Ulrike Förster‐Ruhrmann, Heidi Olze, et al.
Allergy (2024) Vol. 79, Iss. 11, pp. 3108-3117
Open Access | Times Cited: 6
Dupliumab therapy for alopecia areata: a case series and review of the literature
Jundong Huang, Jian Jia, Tingting Li, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 5
Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis
Celeste M. Boesjes, Esmé Kamphuis, Marlies de Graaf, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 10, pp. 1044-1044
Closed Access | Times Cited: 5
Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: A retrospective analysis
Cataldo Patruno, Luca Potestio, Gabriella Fabbrocini, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 12
Closed Access | Times Cited: 20
Ocular surface disease in moderate‐to‐severe atopic dermatitis patients and the effect of biological therapy
Roselie Achten, Judith L. Thijs, Marlot van der Wal, et al.
Clinical & Experimental Allergy (2024) Vol. 54, Iss. 4, pp. 241-252
Open Access | Times Cited: 4
Increasing dosing intervals for biologics in atopic dermatitis‐why, who, when and how?
M. E. Jacobson, Celeste M. Boesjes, Marjolein de Bruin‐Weller, et al.
Journal of the European Academy of Dermatology and Venereology (2025)
Closed Access
Thymus and activation-regulated chemokine (CCL17) as a clinical biomarker in atopic dermatitis: significance and limitations in the new treatment era
Yoko Kataoka
Frontiers in Allergy (2025) Vol. 5
Open Access
What Does Long-Term Control in Atopic Dermatitis Look Like?
Shanthi Narla, Zelma C. Chiesa Fuxench, Katrina Abuabara, et al.
Dermatitis (2025)
Closed Access
Upadacitinib Dose Reduction Regimen in Elderly Patients with Atopic Dermatitis, Guided by Treat-to-Target Consensus Recommendations
Zequn Tong, Xueting Zeng, Feng Huang, et al.
American Journal of Clinical Dermatology (2025)
Closed Access
Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials
Sonja Ständer, Gil Yosipovitch, Eric L. Simpson, et al.
Advances in Therapy (2025)
Open Access
Long-term Outcomes of New Systemic Agents in Atopic Dermatitis: Drug Survival Analyses and Treatment Patterns in Daily Practice
Anne R. Schlösser, Lars Nijman, Renske Schappin, et al.
Acta Dermato Venereologica (2025) Vol. 105, pp. adv41504-adv41504
Open Access
Dupilumab‐Associated Ocular Surface Disease in Paediatric Atopic Dermatitis Patients: Results From the BioDay Registry
Lisa P. van der Rijst, Chantal M. van Luijk, Susan van der Kamp, et al.
Clinical & Experimental Allergy (2025)
Open Access
Dupilumab Monthly Dose De‐Escalation Maintains Efficacy in CRSwNP: A Two‐Year Real‐World Study
Eugenio De Corso, Claudio Montuori, Gabriele De Maio, et al.
The Laryngoscope (2025)
Open Access
Sustained Efficacy and Low Rate of Adverse Events of Dupilumab in Type‐2 CRSwNP Over 48 Months
Pietro Orlando, Giuseppe Licci, Gennaro Illiano, et al.
The Laryngoscope (2025)
Closed Access
Successful dose reduction of dupilumab in atopic dermatitis
Michael R. Ardern‐Jones, Emily E Buchanan, Samba Njungu, et al.
British Journal of Dermatology (2023) Vol. 188, Iss. 5, pp. 678-679
Open Access | Times Cited: 9
Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice?
Luca Mastorino, Federica Gelato, Irene Richiardi, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 5
Closed Access | Times Cited: 8
IgE levels in patients with atopic dermatitis steadily decrease during treatment with dupilumab regardless of dose interval
Coco Dekkers, Marlot van der Wal, Leonie van den Noort, et al.
Clinical & Experimental Allergy (2023) Vol. 53, Iss. 11, pp. 1222-1225
Open Access | Times Cited: 8
Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study
Andrea Chiricozzi, Giacomo Dal Bello, Niccolò Gori, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 7
Chronische Rhinosinusitis mit nasalen Polypen – Verlängerung der Dupilumab-Therapieintervalle
Heike Appel, Robin Lochbaum, Thomas K. Hoffmann, et al.
HNO (2024) Vol. 72, Iss. 7, pp. 499-503
Open Access | Times Cited: 2
An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024
Michael R. Ardern‐Jones, Sara Brown, Carsten Flohr, et al.
British Journal of Dermatology (2024)
Closed Access | Times Cited: 2
Biological Tipping Point in Patients with Atopic Dermatitis Treated with Different Dosing Intervals of Dupilumab
Coco Dekkers, Marlot van der Wal, Mohsin El Amrani, et al.
Journal of Investigative Dermatology (2023) Vol. 143, Iss. 9, pp. 1822-1825.e3
Open Access | Times Cited: 5
How to Understand Personalized Medicine in Atopic Dermatitis Nowadays?
Alicja Mesjasz, Karol Kołkowski, Andreas Wollenberg, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7557-7557
Open Access | Times Cited: 4
Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gaps
Lisa P. van der Rijst, Annet van Royen‐Kerkhof, Suzanne G.M.A. Pasmans, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top